Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

March 2, 2018: By Jon Swedien

Aerie Pharmaceuticals anticipates it will launch Rhopressa in the middle of Q2-2018, the company announced Feb. 28.

Aerie forecasts the open-angle glaucoma and ocular hypertension treatment will net between $20 million and $30 million in 2018, the company said. Rhopressa gained US FDA approval in December 2017.

The company said it expects to gain preferred formulary coverage for the majority of commercial payers for Rhopressa by late 2018, with most of the Medicare Part D coverage expected to start in 2019.

Aerie said it has commercial product and sample inventory currently on hand to cover more than a full year of expected demand. The company also plans to have its sales force of 100 territory managers in place and fully trained in time for the launch, said Vicente Anido Jr., PhD, Aerie’s chairman and CEO.

Aerie forecasts its cash burn for 2018 will range between $200 million to $210 million. That includes adjusted total operating expenses in the range of $155 million to $160 million, and capital and inventory build expenditures in the range of $45 million to $50 million, the company said.

Aerie had approximately $250 million in cash, cash equivalents, and investments as of Dec. 31, 2017, the company said.

In January, Aerie raised approximately $136 million in equity offering net proceeds from the issuance of 2.3 million shares, the company reported.

Rhopressa (netarsudil ophthalmic solution) 0.02% is a rho-associated protein kinase (rho kinase, or ROCK) inhibitor, a new class of medications proposed to lower intraocular pressure (IOP) by directly increasing trabecular outflow. The eye drop is administered once a day.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT